Ezallor Sprinkle is a medicine owned by Sun Pharm and contains the active ingredient rosuvastatin calcium. It was first authorized for market use on 18 December 2018. Ezallor Sprinkle is available in capsule; oral dosage forms.
The generic version of Ezallor Sprinkle can possibly be released after 12 February 2036, once the patent holding exclusively expires.
The active ingredient in Ezallor Sprinkle, rosuvastatin calcium, is used to manage high blood cholesterol and related conditions.
Ezallor Sprinkle holds one patent, the last of which will expire on 12 February 2036, paving the way for the release Ezallor Sprinkle generic. Below are the details of the patent: